Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Zifanocycline (KBP-7072) in Healthy Subjects
NCT02454361Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- May 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zifanocycline in acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CAP) and Intra-abdominal infection (IAI) (6 arms), sponsored by KBP Biosciences. Primary endpoint: Number of participants with adverse events at 10 days. Started May 2015; status: completed.
02
Drugs
zifanocycline
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)community-acquired bacterial pneumonia (CAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT02454361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454361.